# Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease

> **NCT02738905** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Jason Stubbs, MD**

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT02738905
- **Lead sponsor:** Jason Stubbs, MD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-01
- **Primary completion:** 2019-02-26
- **Final completion:** 2019-02-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** insufficient support
- **Last updated:** 2019-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02738905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02738905, "Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02738905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*